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Abstract 
 
Aims: To evaluate endothelial-dependent and –independent cutaneous vasodilator responses in the 
feet of patients with peripheral arterial disease (PAD) with or without Type 2 diabetes. 
 
Methods: Cutaneous microvascular responses in the dorsum of both lower limbs were measured in 
the supine position using Laser Doppler Fluximetry combined with iontophoretic administration of 
endothelial-dependent (acetylcholine, Ach) and -independent (sodium nitroprusside, SNP) 
vasodilators in diabetic (n=19) and non diabetic (n=17) patients with PAD (presenting as unilateral 
calf intermittent claudication (IC). 
 
Results: In patients with diabetes and IC, endothelial-dependent vasodilation was significantly 
impaired in the symptomatic limb [74 (57,105) vs 68 (24,81) PU, Z= -2.79, p=0.005] compared to 
the asymptomatic limb. Patients without diabetes showed no impairment of vasodilation.  Resting 
ankle-brachial pressure index did not identify the presence of abnormalities in microvascular 
function. 
 
Conclusions: The combination of diabetes and PAD is associated with a reduction in endothelial-
dependent cutaneous vasodilation in the feet without an associated reduction in endothelial 
independent vasodilation. 
 
 
 
 
 
 
 
 
 
Introduction 
Diabetes (Type 1 and 2) affects almost 3% of the global population (estimated to rise up to 4% by 
2030) [1] and consumes more than 10% of the healthcare budget in the U.K (equating to an amount 
greater than £12 billion in 2012) [2].  Peripheral Arterial Disease (PAD) is 2-5 fold more common 
in patients with diabetes [3, 4], and the combination of diabetes and PAD is more likely to result in 
critical ischaemia [5], tissue necrosis and/or amputation [6], making diabetic patients with PAD at 
high risk of a negative clinical outcome [6] including adversely affecting their quality of life [social 
activities, mobility, sexual life; 2]. Given the prognosis for patients with diabetes and PAD there is a 
paucity of non-invasive tools to accurately identify those patients with diabetes who are at higher 
risk of developing complications including both cardiovascular and peripheral vascular disease.  
The 2012 NICE guidelines recommend the measurement of Ankle Brachial Pressure Index at rest 
(ABPI), but the value of ABPI in diabetic populations has been questioned [7].  
 
There is evidence that microvascular reactivity may be impaired in patients with stable PAD both at 
rest and during exercise [8, 9], but few, if any, previous studies have evaluated the effects of co-
existent diabetes or assessed cutaneous microvascular responses in the feet of this group of patients.  
Technological developments in Laser Doppler fluximetry (LDF) permit accurate non-invasive 
measurements of cutaneous microvascular reactivity, including vasodilator responses to 
iontophoretic administration of endothelial-dependent and –independent vasodilators [10,11], 
suggesting that this technique may be used in conjunction with ABPI, in evaluating the this 
vulnerable patient population.  Therefore the aim of this study was to assess the cutaneous 
microvascular responses in diabetic patients with PAD, compare symptomatic with asymptomatic 
limbs and propose a measure that could potentially be used to identify patients at particular risk of 
impending tissue breakdown.  
 
 
Patients and Methods 
Thirty-eight patients with unilateral symptoms of peripheral arterial disease (presented in the form 
of intermittent calf claudication) (19 with Type 2 diabetes [T2D] and 19 non-diabetic) provided 
written informed consent to participate in this study which was approved by the Southern 
Derbyshire Local Research Ethics committee and was carried out in accordance with the Declaration 
of Helsinki of the World Medical Association.  Two of them, belonging to the non-diabetic group, 
withdrew prior to the assessments, due to a change in their personal circumstances. Patients with 
signs of peripheral neuropathy, any concomitant vascular disease (eg. Raynaud’s, connective tissue 
disease or vasculitis), venous insufficiency, taking vasoactive medication and those in atrial 
fibrillation and/or with heart failure or peripheral oedema were excluded. No Coronary Artery 
Disease (CAD) or lung disease were reported on any of the participants, and no significant 
differences existed in medication between groups. Demographic data collected, included age, 
gender, resting blood pressure (average of 3 measurements), ABPI, smoking status, total cholesterol 
and HbA1c (Table 1). 
 
Assessment of Microvascular Function 
After 30 minutes of quiet supine rest in a temperature-controlled room, baseline cutaneous blood 
flux was first measured on the dorsum of the foot of the symptomatic leg) using LDF (Moor 
Instruments Ltd, Axminster, UK).  Endothelial-dependent and independent vasodilators, ACh (1%) 
and SNP (1%) respectively, were administered transcutaneously by iontophoresis (0-2000C), as 
described previously [10, 11].  Incremental vasodilator responses were measured by LDF and 
automatically captured using the Moorsoft for windows DRT4 software program (V1.2, Moor 
Instruments, UK).  Microvascular responses using the same protocol were then repeated in the 
contralateral foot (asymptomatic leg). The differences between Maximum Perfusion and mean 
baseline Perfusion to both ACH/SNP were analysed. 
 
Statistical Analysis 
Data are presented as the mean ±S.D, and the median and interquartile ranges (25% and 75%). 
Significant differences were accepted at the 5% level and non-parametric tests (Wilcoxon Signed 
Ranks Test) were used to compare differences between groups. 
 
Results 
Patient Characteristics 
Thirty-six patients with PAD (unilateral calf claudication) completed the study: nineteen T2D (11M, 
aged 649 years) and seventeen non-diabetic patients (17M, aged 658 years) (Table 1).  There 
were no statistically significant differences in the baseline demographic data (including drug 
prescription and smoking status). ABPI was significantly lower in the symptomatic compared with 
the asymptomatic limbs in both groups (0.59 [0.47, 0.75] vs 0.88 [0.70, 0.97], Z= -3.30, p=0.001, in 
non-diabetic patients; and 0.66 [0.50, 0.82] vs 0.84 [0.79, 1.10], Z= -2.31 p=0.02, in diabetic 
patients). 
 
Microvascular Function 
There were no significant differences in baseline cutaneous flux between symptomatic and 
asymptomatic legs, or between diabetic and non-diabetic patients. All participants had a 
corresponding dose response in both legs. In patients with PAD and T2D, ACh mediated 
Endothelial-dependent vasodilation in the foot was significantly reduced in the symptomatic 
compared with the asymptomatic leg (74 [57, 105] vs 68 [24, 81] PU, Z= -2.79, p=0.005; Figure 1].  
There was no corresponding difference in SNP mediated endothelial independent between the two 
limbs (101 [77, 137] vs 78 [57, 109] PU, Z= -1.51, p=0.07; Figure 2].  
 
Discussion 
With the year by year increase in the prevalence of diabetes (estimated to reach 4% of the global 
population by 2030) [1] it is no surprise that the prevention and treatment of diabetes is high on the 
public health agenda.  The heavy economic burden on health systems in the order of £12 billion per 
annum [2] is accompanied by a major impact on the patients’ quality of life [2]. Furthermore, the 
rate of amputation ranges currently from 5.5% (major amputations) to 22.6% (minor amputations) 
in the diabetic population [12], with the presence of PAD being identified as a key risk factor for 
amputation in this patient group [13]. Given that the prevalence of PAD in patients with diabetes 
may reach up to 20.6% [3] it is important to identify those patients who are at greater risk of a 
negative clinical outcome. Hodges et al. [8] and Rossi et al. [9] have demonstrated that 
microvascular reactivity is impaired, both at rest and during exercise, in patients with stable PAD. 
The present study has, for the first time, identified an impairment of microvascular endothelial-
dependent vasodilatory function in the symptomatic limbs of patients with IC and T2D but no 
difference in endothelium-independent function. We postulate that the cumulative effect of T2D 
(e.g. a reduction in the capillary size and thickening of basement membranes; [14]) and PAD (e.g. 
chronic generalized pro-inflammatory state associated with the development of atherosclerosis; 
[15]) in the symptomatic limb leads to a net impairment of endothelium-dependent vasodilation: if 
these findings were purely due to T2D, ACh-mediated vasodilation would also be impaired in the 
asymptomatic leg.  
 
Abnormalities within the cutaneous circulation are not considered in IC, as by definition, there are 
no skin changes linked with this condition. However, our work, highlighting the differences 
between the symptomatic and asymptomatic leg, suggest an interaction between the development of 
peripheral arterial disease and T2D, with respect to microvascular dysfunction in general and 
endothelial dysfunction in specific. These effects may be additive and therefore, as the diabetic 
population is prone to rapid disease progression, microcirculatory findings may be useful for risk 
stratification.  Although, the complex structure of the dermal vascular bed offers limited 
possibilities for studying the skin microcirculation in everyday practice, the use of non-invasive, 
relatively-inexpensive methods such as Laser Doppler Fluximetry and Imaging, can provide 
monitoring of microcirculatory parameters as a part of integrated diagnostic approach that could 
evaluate the risk and the effectiveness of the diagnostic approaches used, as it has been suggested 
for other conditions within the same population [16].  
 
In this study demographic and biochemical data were equally matched within the subject groups 
(Table 1). However, they were not a homogenous group with respect to claudication severity, even 
though they presented with calf claudication. Follow up studies could consider using maximum 
walking distance, treadmill studies and Duplex ultrasound assessments to provide detailed 
information with respect to the identification and assessment of the degree of arterial disease.   
 
For both diabetic and non-diabetic groups, there was a significantly higher ABPI in the 
asymptomatic legs. However, there must be cautious interpretation of the ABPI values within the 
diabetic subjects as these readings may be falsely raised due to calcification, especially those with 
long standing diabetes [17]. It is recommended that future studies include the measurement of toe 
pressures. 
 
 In summary, we have presented data documenting microvascular dysfunction in the symptomatic 
limbs of diabetic patients with peripheral arterial disease. Although a larger number of participants 
may have added further significance to our findings (e.g. additional statistically-significant 
differences between groups as far endothelial-independent vasodilation is concerned), our current 
findings show that microvascular dysfunction may contribute to the development of arterial 
complications in patients with diabetes. Further studies are needed in larger patient groups to 
investigate the longer term prognostic information in patients with diabetes and PAD to identify 
patients at high risk of developing ulcers and PAD leading to amputation. At present we have 
validated techniques including ultrasound and Doppler for the assessment of macro vascular 
structural and flow abnormalities which contribute to symptoms of claudication. However, it has 
remained a challenge for clinicians to be able to risk stratify patients who are more likely to 
deteriorate and develop cutaneous abnormalities including skin ulceration. We have shown that the 
microvascular function in symptomatic legs of diabetic claudicants to have evidence of dysfunction 
which may contribute to the future development of skin ulceration. This is a new finding deserving 
further research. 
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Table 1 Patient Clinical Characteristics 
 
Clinical 
Characteristics 
Non Diabetic 
N=17 
T2D 
N=19 
p Value 
Age (years) 65.2 8.1 64.5 9.1 0.86 
BMI 26.1 3.6 27.4 4.5 0.43 
Systolic BP 
(mmHg) 
151.1 24.5 159.3 26.6 0.55 
Diastolic BP 
(mmHg) 
82.1 10.2 80.1 9.4 0.78 
Total 
Cholesterol 
(mmol/L) 
4.8 1.0 5.2 1.0 0.65 
ABPI 
(symptomatic) 
0.59 0.28 0.66 0.32 0.41 
ABPI 
(asymptomatic) 
0.88 0.27 0.84 0.31 0.83 
HbA1c (%)  8.4 1.6  
 
 
 
 
 
Figure 1: ACh response (PU) in Asymptomatic and Symptomatic T2D legs.  
Figure 2: SNP response (PU) in Asymptomatic and Symptomatic T2D legs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1 
 
Figure 2 
